---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-008807"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T14:26:11.944814+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regeneron appoints Christopher Fenimore as CFO to succeed retiring Robert Landry

## Summary
- Christopher Fenimore promoted to SVP, Finance and CFO; effective day after 2023 10-K filing (expected Feb 5, 2024).
- Jason Pitofsky promoted to VP, Controller; no change in compensation.
- Fenimore's base salary increased to $660,000; granted equity award with target fair value of $5,000,000.
- Equity award includes options for 8,499 shares (4-year vest) and 2,370 RSUs (50% at years 2 and 4).
- Succession plan previously disclosed; Landry retiring.

## SEC filing metadata
- accession: 0001104659-24-008807
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/tm244671d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-008807
- JSON: https://secwatch.observer/filing/0001104659-24-008807.json
- Plain text: https://secwatch.observer/filing/0001104659-24-008807.txt

## Key facts
- Executive change
  Robert E. Landry departed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..
  - Action: retiring
  - Role: Chief Financial Officer
  source text: the current Chief Financial Officer, Robert E. Landry, who is retiring.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm
- Executive change
  Christopher Fenimore was appointed as Senior Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Senior Vice President, Finance and Chief Financial Officer
  source text: appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm
- Executive change
  Jason Pitofsky was appointed as Vice President, Controller at REGENERON PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Vice President, Controller
  source text: appointed Jason Pitofsky, currently the Company’s Vice President, Accounting and Financial Reporting, as Vice President, Controller.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465924008807/0001104659-24-008807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.